RAINBOW

Study Design: Phase II/II, randomised, multicenter

Patients: treatment naive WM patients

Treatment: Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC)

Status of the Study: patient recruitment closed (last patient in November 2021, n= 53)

Sponsor: University College, London

further information